Xeris Biopharma (NASDAQ:XERS) Insider Sells $141,150.00 in Stock

by · The Markets Daily

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) insider Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $9.41, for a total transaction of $141,150.00. Following the completion of the transaction, the insider directly owned 1,599,208 shares of the company’s stock, valued at approximately $15,048,547.28. This trade represents a 0.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Mcculloch also recently made the following trade(s):

  • On Monday, September 28th, Kevin McCulloch sold 25,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00.
  • On Tuesday, September 1st, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.49, for a total value of $127,350.00.
  • On Monday, August 3rd, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.02, for a total value of $120,300.00.

Xeris Biopharma Stock Performance

XERS opened at $9.08 on Monday. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 17.00. Xeris Biopharma Holdings, Inc. has a 12-month low of $5.25 and a 12-month high of $11.33. The business has a 50 day moving average of $8.46 and a 200-day moving average of $7.32. The stock has a market cap of $1.66 billion, a price-to-earnings ratio of -82.55 and a beta of 0.53.

Xeris Biopharma (NASDAQ:XERS – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%.The business had revenue of $92.10 million for the quarter, compared to analyst estimates of $90.12 million. On average, equities research analysts expect that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current year.

Wall Street Analyst Weigh In

XERS has been the topic of several research analyst reports. Barclays increased their price objective on shares of Xeris Biopharma from $9.00 to $12.00 and gave the company an “overweight” rating in a research report on Thursday, August 20th. Leerink Partners upped their price target on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a research note on Thursday, September 10th. Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Finally, Wall Street Zen upgraded shares of Xeris Biopharma from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Xeris Biopharma currently has an average rating of “Hold” and an average price target of $12.80.

Get Our Latest Stock Report on Xeris Biopharma

Institutional Trading of Xeris Biopharma

Several institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. bought a new position in Xeris Biopharma in the 2nd quarter valued at approximately $115,042,000. Wellington Management Group LLP grew its holdings in Xeris Biopharma by 8.9% during the 2nd quarter. Wellington Management Group LLP now owns 2,365,103 shares of the company’s stock worth $18,732,000 after acquiring an additional 193,749 shares during the last quarter. Legal & General Group Plc acquired a new position in Xeris Biopharma in the 2nd quarter valued at approximately $15,941,000. Parkman Healthcare Partners LLC bought a new position in shares of Xeris Biopharma during the second quarter valued at $14,316,000. Finally, Algert Global LLC raised its stake in shares of Xeris Biopharma by 50.6% during the second quarter. Algert Global LLC now owns 1,742,942 shares of the company’s stock valued at $13,804,000 after acquiring an additional 585,984 shares during the last quarter. 42.75% of the stock is currently owned by institutional investors.

Xeris Biopharma Company Profile

(Get Free Report)

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology, and related rare or chronic conditions. The company uses proprietary formulation technologies designed to deliver medicines that are difficult to formulate or administer through conventional methods, including its XeriSol and XeriJect platforms.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection used to treat severe hypoglycemia; Keveyis (dichlorphenamide), a treatment for primary periodic paralysis; and Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with Cushing’s syndrome.

Recommended Stories